started · updated
Infarmed reports daily adverse reactions for weight loss drugs in Portugal
Infarmed, the Portuguese national medicines authority, has reported an average of one suspected adverse reaction per day regarding weight loss and diabetes medications in 2026. Between January 1, 2024, and September 21, 2026, a total of 695 notifications were recorded involving four active substances in the GLP-1 receptor agonist class.
Tirzepatide, the active ingredient in Mounjaro, accounts for the majority of these reports, with 186 notifications recorded through September 21, 2026. Other substances mentioned include semaglutide (used in Ozempic and Rybelsus), dulaglutide (Trulicity), and liraglutide (Victoza and Saxenda). Reported symptoms include vomiting, diarrhea, and hair loss.
The increase in notifications coincides with a significant rise in the use of these medications. For instance, tirzepatide distribution in Portuguese community pharmacies grew from 10,689 packages in 2024 to 434,768 in 2025. Infarmed noted that while notification rates fluctuate, they have remained relatively stable over the years.
Entities
Claims
What the coverage asserts, and how many sources carry each claim.
- [● 3 SOURCES] A total of 695 notifications regarding four GLP-1 receptor agonist substances were recorded between January 1, 2024, and September 21, 2026. recordeuropa.com · www.cmjornal.pt · observador.pt
- [● 3 SOURCES] Infarmed reports that the rate of suspected adverse drug reactions (ADRs) has remained relatively stable over the years. recordeuropa.com · www.cmjornal.pt · observador.pt
- [● 2 SOURCES] Semaglutide usage also showed high volumes, with 626,142 packages recorded in 2025. recordeuropa.com · observador.pt
- [● 2 SOURCES] The number of tirzepatide packages in Portuguese community pharmacies rose from 10,689 in 2024 to 434,768 in 2025. recordeuropa.com · observador.pt
- [● 2 SOURCES] Tirzepatide, the active substance in Mounjaro, accounts for the majority of the notifications. recordeuropa.com · observador.pt
- [● 2 SOURCES] Reported adverse reactions include vomiting, diarrhea, and hair loss. www.cmjornal.pt · observador.pt